gene editing

News

Beam cuts one in five staffers to conserve cash

Gene-editing company Beam Therapeutics has shifted into reverse, slashing staff and R&D programmes after a period of expansion since its public debut in 2020.

News

AZ builds in genomic medicine with $1bn Pfizer deal

AstraZeneca's rare diseases unit Alexion has agreed to pay $1 billion to acquire Pfizer's early-stage gene therapy pipeline and enabling technologies - the company's first

News

FDA sets Dec deadline for Vertex, CRISPR sickle cell therapy

The FDA has started a priority review of Vertex Pharma and CRISPR Therapeutics’ exagamglogene autotemcel (exa-cel) in sickle cell disease (SCD), with a decision on approva

News

Vertex/CRISPR file first gene-editing therapy with FDA

Vertex Pharma and CRISPR Therapeutics have become the first companies to file for FDA approval of a therapy based on gene-editing technology.

News

Double blow for Sangamo as Novartis, Biogen exit deals

The two deals for gene-modifying candidates were worth up to $3.1 billion including milestones.

News

After disappointing trial, Editas puts lead CRISPR drug on h...

Gene-editing specialist Editas Medicine has halted development of its lead clinical programme for congenital eye disorders after it generated lacklustre results in a phase 1/2 trial.

Beam cuts one in five staffers to conserve cash

AZ builds in genomic medicine with $1bn Pfizer deal

FDA sets Dec deadline for Vertex, CRISPR sickle cell therapy

Vertex/CRISPR file first gene-editing therapy with FDA

Double blow for Sangamo as Novartis, Biogen exit deals

After disappointing trial, Editas puts lead CRISPR drug on h...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

gene editing

Editor's Picks